

Artificial Intelligence in U.S. Healthcare: Legal Framework, Liability, and Ethical Challenges with Special Focus on Pediatric Care

Authors:

Torres Ponce, Mariano Enrique
Lawyer specialized in Computer Law

Arana, María Noel
Doctor specialized in Pediatrics and Neonatology

ABSTRACT

This article maps the fast-evolving U.S. regulatory environment for AI in healthcare and translates it into operational guidance with a pediatric lens. We distinguish ML-SaMD from CDS and identify lifecycle control points, including data curation, validation, PCCP, deployment, and monitoring. We then examine how the 21st Century Cures Act boundary for non-device CDS, FDA device pathways, HIPAA and HITECH privacy rules, and ONC HTI-1 transparency obligations interact in real clinical settings. Building on that analysis, the paper presents a responsibility matrix that allocates duties across manufacturers, institutions, clinicians, and EHR vendors, and proposes a pediatric safety framework that requires validation stratified by age, transparency that is usable in clinical practice, and drift monitoring linked to clear escalation protocols. We argue that current law only partially addresses algorithmic opacity, fairness, and the long-term outcome risks specific to children, and we offer policy and implementation recommendations to close these gaps. The result is actionable guidance for legal practitioners, health systems, and developers seeking to reconcile safety, equity, and continuous learning in AI enabled care.

KEYWORDS:

Artificial intelligence in healthcare; ML-SaMD; Clinical Decision Support (CDS); Decision Support Interventions (DSI); FDA regulation; ONC HTI-1; HIPAA/HITECH; liability; algorithmic transparency; pediatric safety; fairness.

TABLE OF CONTENTS

A. INTRODUCTION

B. TECHNICAL FOUNDATIONS FOR LEGAL PRACTITIONERS

B.1. Defining the AI Healthcare Ecosystem

B.2. Machine Learning Lifecycle in Healthcare: Regulatory Control Points

C. U.S. REGULATORY FRAMEWORK FOR AI IN HEALTHCARE

C.1. The 21st Century Cures Act and the CDS Non-Device Exemption

C.2. FDA Software as Medical Device Framework Evolution

C.3. HIPAA, HITECH, and Pediatric Data Considerations

C.4. ONC HTI-1 Decision Support Interventions and EHR transparency

C.5. Institutional Responsibility Matrix

D. LIABILITY AND STANDARD OF CARE

D.1. Traditional Medical Malpractice Framework

D.2. Product Liability Intersection

D.3. Clinical Documentation and Independence Requirements

D.4. Emerging Jurisprudential Patterns

E. PRIVACY, SECURITY, AND DATA GOVERNANCE

E.1. HIPAA Boundaries in AI Training and Deployment

E.2. Vendor Risk Management and Clinical SBOMs

E.3. Data Minimization Versus Learning Optimization

E.4. Algorithmic Impact Assessment Frameworks

F. FAIRNESS AND NON-DISCRIMINATION

F.1. Documented Cases of Algorithmic Discrimination

F.2. Civil Rights and Healthcare Access Obligations

F.3. Bias Auditing and Fairness Metrics

F.4. Constitutional and Regulatory Constraints

F.5. Insurance and Coverage Implications

G. ARTIFICIAL INTELLIGENCE IN PEDIATRIC CARE: SPECIAL CONSIDERATIONS

G.1. Technical Challenges Unique to Pediatric Populations

G.2. Legal Framework Specificities for Minors

G.3. Current Pediatric AI Applications and Outcomes

G.4. Pediatric-Specific Ethical Considerations

G.5. Proposed Pediatric AI Safety Framework

H. CASE STUDIES AND LEGAL PRECEDENTS

H.1. Epic Systems Sepsis Algorithm: Lessons from Implementation

H.2. IBM Watson for Oncology: Promise Versus Reality

H.3. Babylon Health Chatbot: Regulatory Response and Liability

H.4. Successful Implementations: Radiology CAD Systems

I. RECOMMENDATIONS AND IMPLEMENTATION ROADMAP

I.1. For Regulators and Policymakers

I.2. For Healthcare Institutions

I.3. For Technology Developers

I.4. Pediatric-Specific Implementation Priorities

J. CONCLUSIONS

K. BIBLIOGRAPHY

A. INTRODUCTION

The increasing prominence of artificial intelligence systems in American healthcare generates a fundamental conflict: we ask tools with opaque reasoning to inform high-stakes clinical decisions, including analgesia management in infants. What initially constituted a theoretical concern about “black box” systems has transformed into a pressing clinical reality, particularly in pediatrics, where developmental trajectories and long-term outcomes demand exceptional precision and care.

Since the 21st Century Cures Act (2016), modest CDS tools have evolved into advanced ML systems with near-clinical performance. This evolution has outpaced legal and ethical frameworks, exposing regulatory gaps that threaten both innovation and patient safety.¹

In pediatrics, this challenge acquires particular dimensions. Children, who represent 22% of the U.S. population, present developmental trajectories and long-term vulnerabilities that AI systems trained mainly on adult data address only partially. Errors in pediatric diagnosis can have consequences lasting decades, while data scarcity perpetuates undertraining precisely where accuracy matters most.²

This analysis addresses three fundamental questions shaping the future of AI in American healthcare:

- When does clinical software transition from a tool to a regulated medical device under FDA oversight, impacting liability, innovation, and patient protection?
- What does the standard of care require when physicians rely on algorithmic recommendations whose logic remains opaque to both practitioners and patients?
- How can the competing demands of safety, equity, and continuous learning be reconciled in AI systems, particularly for vulnerable pediatric populations where developmental considerations amplify these challenges?

The regulatory landscape presents a complex web of federal oversight through the FDA, data privacy requirements under HIPAA and HITECH, and emerging state-level initiatives addressing algorithmic accountability. Simultaneously, traditional theories of medical malpractice strain to accommodate scenarios where harm results from

¹ 21st Century Cures Act, Pub. L. No. 114-255, § 3060 (2016)

² Brazelton, T. Berry. “Infants and Mothers: Differences in Development”. New York: Delta (1969)

algorithmic bias, training data inadequacies, or the inscrutability of machine learning models. Insurance frameworks, informed consent processes, and quality assurance mechanisms all require fundamental reconceptualization.

Our investigation reveals that while the United States has achieved significant progress in establishing regulatory pathways for AI medical devices, important gaps persist. The current framework addresses only partially the special needs of pediatric populations, leaves open questions about how to promote meaningful algorithmic transparency, and offers limited guidance on liability allocation when AI systems fail. Furthermore, the accelerated pace of technological development presents an ongoing challenge for regulators, with new capabilities emerging more rapidly than oversight mechanisms can reasonably evolve.

Regulators should require age-stratified reporting and align transparency obligations with device labeling. Institutions ought to create governance committees and maintain local validation records. Developers must provide transparency artifacts and pediatric metrics. Pediatric care specifically demands conservative defaults and human oversight in high-risk contexts. Together these measures create a pragmatic pathway for safe and equitable AI in healthcare.

The purpose of this article is to translate a fragmented legal landscape into an operational framework for pediatric-relevant AI, focusing on regulatory interpretation, liability allocation, and institutional safeguards.

B. TECHNICAL FOUNDATIONS FOR LEGAL PRACTITIONERS

To navigate the regulatory, liability, and ethical complexities outlined in the introduction, a clear understanding of the technical underpinnings of healthcare AI is essential, particularly for addressing the distinct requirements of pediatric care. We define the healthcare AI ecosystem, distinguish generative from discriminative systems, outline the ML-SaMD lifecycle from data curation through training and validation to deployment and ongoing monitoring, and clarify the distinction between transparency and explainability. The objective remains descriptive: mapping the concepts that subsequently anchor regulatory classification, liability analysis, and pediatric-specific safeguards.

To facilitate comprehension for legal practitioners, key terms are defined: Machine Learning Software as a Medical Device (ML-SaMD) refers to AI-driven software performing medical functions; Clinical Decision Support (CDS) refers to tools that aid clinician decision-making. Under ONC's HTI-1 certification program, the corresponding certification criterion is Decision Support Interventions (DSI), which requires transparency about data sources, development and validation methods, and known limitations. Predetermined Change Control Plans (PCCPs) cover pre-approved model updates for ML-SaMD. The Trusted Exchange Framework and Common Agreement (TEFCA) establishes a nationwide health information exchange framework; it does not itself guarantee security. These concepts anchor the regulatory, liability, and pediatric considerations explored herein.

B.1. DEFINING THE AI HEALTHCARE ECOSYSTEM

Before examining legal frameworks, it is necessary to establish clear definitions that bridge technical precision with legal operability. ML-SaMD refers to machine learning-based medical software that produces diagnostic or therapeutic information without requiring direct physician interpretation for each output.³ This category differs from traditional health IT tools because it functions as a medical device in the regulatory sense. A central regulatory distinction is between discriminative and generative systems. Discriminative models classify inputs within bounded categories, such as radiology applications for tumor detection. Generative models, by contrast, can produce new content, including clinical notes or therapeutic recommendations. This open-ended capacity introduces additional complexity for validation, explainability, and liability allocation.

A further challenge, foreign to traditional medicine, is algorithmic drift. ML-SaMD systems are not static instruments with predictable decay but dynamic entities whose performance can silently erode as patient populations evolve or clinical practices advance. This inherent instability disrupts the traditional regulatory paradigm and requires a framework of continuous monitoring. Real-world performance frequently diverges from controlled trial results, as systems encounter patient populations, clinical workflows, and data quality conditions not represented in development environments.

³ FDA, Software as a Medical Device (SaMD): Clinical Evaluation, FDA-2016-D-2483 at 8-12 (2017).

This opacity challenge has been extensively documented in autonomous systems analysis, where the inability to interpret intermediate neural network layer operations creates fundamental accountability concerns. The phenomenon becomes particularly acute in healthcare settings where clinical decision-making requires not merely accurate outputs but comprehensible reasoning that physicians can evaluate, validate, and explain to patients. When AI systems process hundreds of variables through multiple hidden layers in ways that defy simple explanation, they challenge the fundamental premise of informed medical judgment, regardless of their accuracy rates.⁴ These challenges underscore why lifecycle management, from data curation to post-market monitoring, must be analyzed not only as a technical process but as a series of regulatory control points.

B.2. MACHINE LEARNING LIFECYCLE IN HEALTHCARE: REGULATORY CONTROL POINTS

Having established the foundational concepts of the AI healthcare ecosystem, including ML-SaMD definitions and the challenges of explainability, the machine learning operations lifecycle introduces critical regulatory control points, particularly for pediatric applications where data limitations necessitate specialized approaches. Data curation and preprocessing establish the foundation for model accuracy and introduce the first opportunities for bias introduction. Training data selection, cleaning protocols, and feature engineering decisions embed assumptions about patient populations and clinical contexts that persist throughout the system's operational life.

Model training and validation phases require adherence to good machine learning practice guidelines, including appropriate train-test-validation splits, cross-validation strategies, and performance metric selection.⁵ For pediatric applications, this stage must address the critical issue of limited data availability through techniques such as transfer learning from adult populations, synthetic data generation, or federated learning across institutions.⁶

Model deployment marks the transition from development environment to clinical reality, requiring integration with electronic health record systems, clinical workflows, and

⁴ Torres Ponce, Mariano Enrique “Derechos y desafíos de la Inteligencia Artificial” Ciencia y Técnica Administrativa. (2018).

⁵ FDA, Machine Learning-enabled Medical Devices: Guiding Principles, FDA-2021-D-0538 at 15-18 (2021).

⁶ Burns et al., “Pediatric Clinical Decision Support Systems: A Systematic Review and Meta-analysis,” JAMA Pediatrics 174, no. 12 (2020): 1184-1194.

existing decision-support tools. The FDA's Predetermined Change Control Plan framework allows for pre-approved modifications during this phase, provided they remain within specified parameters and effectiveness thresholds.

Continuous monitoring and maintenance represent perhaps the most legally complex aspects of ML-SaMD lifecycle management. Continuous monitoring is essential because AI performance can shift as patient populations or clinical practices evolve. Legal frameworks must account for this dynamism while maintaining safety standards.

This technical complexity illuminates why traditional medical device regulations, designed for static instruments with predictable performance characteristics, may require substantial adaptation for AI systems that learn, adapt, and evolve throughout their operational lifetime.

C. U.S. REGULATORY FRAMEWORK FOR AI IN HEALTHCARE

Building on the technical foundations delineated in the previous section, the regulatory landscape for healthcare AI seeks to balance innovation with patient safety, particularly in pediatric applications where precision is paramount. The regulatory web creates overlapping jurisdictions and compliance obligations that require careful navigation by developers, healthcare institutions, and clinical practitioners seeking to implement AI systems responsibly.

C.1. THE 21ST CENTURY CURES ACT AND THE CDS NON-DEVICE EXEMPTION

The regulatory foundation for AI in healthcare begins with the 21st Century Cures Act of 2016, which created the first statutory framework distinguishing certain clinical decision support software from regulated medical devices.⁷ Section 3060 establishes that CDS functions are not medical devices when they enable healthcare providers to independently review recommendations, provide rationale for recommendations, do not replace independent medical judgment, and allow practitioners to determine appropriateness for specific patients.

⁷ 21st Century Cures Act § 3060(a).

However, these seemingly straightforward criteria become complex when applied to modern AI systems. Independent review capability assumes physicians can meaningfully evaluate algorithmic recommendations, yet algorithmic opacity complicates clinical assessment in practice. A radiologist may receive an AI-generated probability score for lung nodule malignancy but may not be able to examine the pixel-level features that contributed to the calculation. The ability to accept or reject the recommendation constitutes “independent review” when the underlying logic remains opaque remains an open question.

The rationale requirement proves even more challenging for machine learning systems. Traditional rule-based CDS can provide explicit decision trees showing how patient data leads to recommendations. Machine learning systems complicate this requirement because their reasoning processes often remain opaque, limiting the capacity for meaningful independent review.

Replacement versus supplementation of medical judgment creates a spectrum rather than a binary distinction. While early CDS tools clearly supplemented physician decision-making by flagging drug interactions or suggesting dosing guidelines, modern AI systems can synthesize complex clinical pictures with accuracy exceeding human specialists. When an AI system demonstrates superior diagnostic accuracy, physician reliance constitutes replacement or appropriate utilization of available tools becomes a matter of ongoing regulatory interpretation.

The FDA has provided guidance through the Digital Health Center of Excellence, establishing a risk-based framework that considers both the healthcare decision-making situation and the level of physician involvement.⁸ Low-risk CDS that supports well-established clinical management typically falls under the non-device exemption, while novel diagnostic or treatment recommendations trigger device regulation.

C.2. FDA SOFTWARE AS MEDICAL DEVICE FRAMEWORK EVOLUTION

While the 21st Century Cures Act delineates boundaries for clinical decision support software exempt from device regulation, the FDA’s evolving Software as a Medical

⁸ FDA Digital Health Center of Excellence, Clinical Decision Support Software: Draft Guidance, FDA-2019-D-1708 at 22-25 (2022).

Device framework provides critical specificity for AI systems, particularly in pediatric applications where risk-based classification ensures patient safety.⁹

Class I devices are lower risk and many are exempt from 510(k) requirements. Basic clinical decision support features such as BMI calculators and simple risk scorecards often receive Class I treatment when regulated.

Class II devices generally require 510(k) clearance demonstrating substantial equivalence to a predicate, and many diagnostic AI systems, including radiological computer assisted detection and diagnosis tools and some predictive analytics platforms, operate under Class II authorization.

Class III devices require the most rigorous premarket approval and are reserved for the highest-risk indications. Depending on their intended use and risk profile, a narrow subset of AI systems may require Class III oversight, particularly those involving autonomous diagnostic or therapeutic functions used in critical care settings.

The 510(k) pathway has presented challenges for AI systems because substantial equivalence focuses on comparison to a predicate device. Traditional devices tend to exhibit stable performance characteristics, which facilitates equivalence assessments. Machine-learning systems may achieve improved performance through mechanisms that differ from the predicate device. This creates regulatory tension where innovative AI systems have difficulty demonstrating equivalence to established comparators even when performance gains are observed.

The De Novo pathway, established for novel devices without an appropriate predicate, has become an important route for AI innovation.¹⁰ It allows FDA to create new device types with special controls calibrated to risk. Notable De Novo authorizations include IDx-DR for autonomous diabetic retinopathy detection and Caption Guidance for echocardiographic image acquisition.

⁹ 21 C.F.R. § 860.3(c)(1)-(3) (2024).

¹⁰ 21 U.S.C. § 360c(f)(2); see also FDA, De Novo Classification Process, FDA-2014-D-1305 (2019).

Predetermined Change Control Plans represent another significant development in oversight of machine-learning-enabled SaMD.¹¹ A PCCP permits predefined, limited algorithm modifications within specified parameters, supported by robust change control, verification and validation, and performance monitoring. This approach recognizes the iterative nature of ML while maintaining safety oversight. Effective implementation depends on mature lifecycle processes that may not yet be uniform across institutions.

In January 2025, the FDA released a Draft Guidance on Artificial Intelligence-Enabled Device Software Functions, proposing recommendations for lifecycle management and marketing submissions of AI-enabled medical devices. The document remains in draft form and has not yet entered into force. The draft emphasizes continuous performance monitoring, risk mitigation strategies, and post-market surveillance, which are particularly critical for pediatric applications where developmental variability and data scarcity demand robust validation to ensure safety and efficacy across diverse patient populations.¹²

C.3. HIPAA, HITECH, AND PEDIATRIC DATA CONSIDERATIONS

Beyond the FDA’s risk-based classification of AI-enabled medical devices, the integration of these systems into healthcare workflows raises critical data privacy and security challenges, particularly for pediatric populations subject to stringent protections under HIPAA, HITECH, and state-specific regulations.¹³ Covered entities including hospitals and physician practices must ensure that AI systems maintain appropriate safeguards for protected health information. Business associates such as AI developers and cloud computing providers must execute agreements guaranteeing equivalent protection levels.

Minimum necessary requirements prove particularly challenging for machine learning systems that may require extensive datasets for effective training. Traditional HIPAA guidance, designed for human access to individual patient records, provides limited direction for algorithmic processing of population-level data. The conflict between data

¹¹ Food and Drug Administration. Predetermined Change Control Plans for Machine Learning-enabled Medical Device Software as a Medical Device. FDA-2023-D-1185 (2024).

¹² Burns et al., “Pediatric Clinical Decision Support Systems: A Systematic Review and Meta-analysis,” *JAMA Pediatrics* 174, no. 12 (2020): 1184-1194.

¹³ Health Insurance Portability and Accountability Act (HIPAA), Pub. L. No. 104-191 (1996); Health Information Technology for Economic and Clinical Health Act (HITECH), Pub. L. No. 111-5 (2009).

minimization principles and AI effectiveness requirements remains unresolved in current regulatory guidance.

For pediatric populations, HIPAA provides enhanced protections for personal representatives and adolescent healthcare decision-making. Parents typically serve as personal representatives for minor children, yet state law variations create complexity. Some states grant adolescents independent healthcare decision-making authority for reproductive health, mental health, or substance abuse treatment, potentially limiting parental access to AI-generated insights in these domains.

COPPA compliance becomes relevant when AI systems interact with children under 13 through patient portals, mobile applications, or educational platforms.¹⁴ COPPA's requirements for verifiable parental consent, data minimization, and third-party sharing restrictions may conflict with AI training needs for comprehensive datasets. Healthcare entities must navigate the intersection of COPPA, HIPAA, and state medical consent laws when implementing pediatric AI applications.

The limitations of HIPAA become even more pronounced in pediatrics, where parental consent, adolescent privacy, and long-term data retention introduce layers of complexity absent in adult populations.

C.4. ONC HTI-1 DECISION SUPPORT INTERVENTIONS AND EHR TRANSPARENCY

The ONC HTI-1 final rule replaces the prior CDS certification criterion with the Decision Support Interventions (DSI) criterion for certified EHR technology and adds transparency requirements, including disclosures on data sources, development and validation methods, known limitations, and special provisions for predictive DSIs. These requirements, which entered into phased implementation in 2024 and will reach full compliance by December 31, 2025, place the transparency obligations on certified health IT developers under the Decision Support Interventions (DSI) certification criterion; implementers must surface these attributes to end users within certified EHR technology.¹⁵

¹⁴ Children's Online Privacy Protection Act (COPPA), 15 U.S.C. §§ 6501-6506 (2013).

¹⁵ 45 C.F.R. § 170.315(b)(11) (Decision Support Interventions); Health Data, Technology, and Interoperability (HTI-1) Final Rule, 89 Fed. Reg. 1196 (Jan. 9, 2024)

Under the DSI criterion, transparency attributes include identification of data sources used in development, the methods for development and validation, known limitations and risks, and performance context. For AI systems, this creates tension between intellectual property protection and regulatory compliance, and developers must balance competitive interests with transparency obligations.

Patient-facing access can be supported within certified EHR technology so that individuals may understand when decision support influenced their care, consistent with applicable law and institutional policy. In pediatric settings, access typically extends to parents or guardians, subject to state-law protections for adolescent confidentiality. Interoperability requirements ensure that DSI content is available within existing EHR workflows and remains portable, reducing vendor lock-in and helping ensure that AI-assisted recommendations become part of the longitudinal health record.

C.5. INSTITUTIONAL RESPONSIBILITY MATRIX

The regulatory framework creates a complex web of overlapping responsibilities among healthcare stakeholders. Manufacturers bear primary responsibility for device safety, effectiveness, and regulatory compliance, including adverse event reporting, quality system maintenance, and post-market surveillance. For AI systems, this extends to algorithm validation, bias mitigation, and performance monitoring across diverse patient populations.

Healthcare institutions serve as device users responsible for appropriate implementation, staff training, and clinical governance. Hospitals must establish AI oversight committees, develop clinical protocols for AI utilization, and maintain documentation standards for algorithmic decision-making. The lack of standardized institutional frameworks creates significant compliance variation across healthcare systems.

Individual clinicians retain ultimate responsibility for patient care decisions, regardless of AI assistance level. Professional licensing boards have yet to establish comprehensive standards for AI utilization, leaving practitioners to navigate ethical and legal obligations with limited guidance. The tension between AI reliance and professional judgment represents one of the most significant unresolved issues in current regulatory frameworks.

EHR vendors occupy a unique position as both business associates under HIPAA and potential device manufacturers if their systems include regulated AI functionality. Many EHR companies have integrated third-party AI tools while attempting to avoid direct regulation through careful feature positioning and liability allocation arrangements.

This intricate responsibility distribution creates potential gaps in oversight and accountability, particularly when AI systems span multiple vendors, institutions, and clinical domains. The pediatric care context amplifies these challenges by introducing additional stakeholders, including parents, schools, and specialized care providers, each with distinct legal relationships and information access rights.

D. LIABILITY AND STANDARD OF CARE

While the regulatory framework outlined above establishes critical boundaries for AI deployment in healthcare, questions of liability emerge when these systems fail to meet clinical expectations, particularly in pediatric contexts where accountability is paramount. Medical malpractice frameworks developed for human decision-making encounter unprecedented challenges when applied to algorithmic recommendations, while product liability doctrines struggle to accommodate systems that learn and evolve after deployment. The interplay among physician negligence, institutional oversight responsibilities, and manufacturer duties creates novel liability scenarios that existing legal frameworks address only partially.

Establishing operational standards of care for AI utilization requires addressing appropriate clinical indications, model validation and drift monitoring procedures, human oversight requirements, comprehensive documentation protocols, and escalation mechanisms for system failures. Pediatric contexts introduce additional complexity through distinct risk profiles, specialized consent frameworks, and long-term outcome considerations that may not manifest until years after AI-assisted care decisions.

D.1. TRADITIONAL MEDICAL MALPRACTICE FRAMEWORK

The foundation of medical liability in the United States rests on negligence principles that require proof of duty, breach of standard of care, causation, and damages.¹⁶ This

¹⁶ Restatement (Second) of Torts § 282 (1965).

framework, developed for human decision-making, faces unprecedented challenges when applied to AI-assisted healthcare.

The physician-patient relationship constitutes the legal and ethical foundation from which the duty of care arises. The integration of autonomous AI systems challenges this traditional dyadic model, introducing a fundamental uncertainty about whether an algorithm's output can independently generate a duty of care in the absence of human agency. This ambiguity forces a re-examination of liability pathways and raises the question of whether responsibility must invariably flow through human intermediaries such as clinicians, manufacturers, and institutions, who control, deploy, and remain ultimately accountable for the system's clinical application.

These challenges are heightened in pediatrics, where physicians must balance parental authority, the evolving capacity of minors, and heightened vulnerability, making any AI-assisted deviation from standard practice particularly fraught with liability.

Standard of care analysis traditionally examines what a reasonably prudent physician would do under similar circumstances. When AI systems demonstrate superior diagnostic accuracy or treatment optimization compared to human practitioners, the standard of care itself becomes contested. At that point, the question is no longer whether physicians should use such tools, but how their use reshapes the very contours of professional judgment.

The locality rule, once dominant in medical malpractice, has largely given way to national standards reflecting physician training uniformity and information accessibility. AI systems accelerate this trend by providing consistent recommendations regardless of geographic location. Yet this very consistency creates new questions about resource allocation and access. If AI-enhanced care becomes the norm in major academic centers, community hospitals may face liability for failing to provide equivalent technological capabilities.

Res ipsa loquitur doctrine allows negligence inference when injuries result from events that would not normally occur without negligence. AI systems complicate this analysis because algorithmic failures may result from subtle bias in training data, adversarial attacks, or system interactions that human operators cannot reasonably prevent or detect.

In this sense, the doctrine confronts its own limits in the age of autonomous systems, where exclusive control becomes more diffuse and responsibility more elusive.

D.2. PRODUCT LIABILITY INTERSECTION

AI medical devices create hybrid liability scenarios that blend medical malpractice with traditional product liability doctrines. While strict liability has long applied to manufacturing defects, design defects, and failures to warn, its application in the AI context presents unique challenges. For instance, issues like corrupted training data, coding errors, or deployment mistakes can be analogized to traditional manufacturing defects. However, the more difficult question arises when machine learning systems function exactly as designed yet produce harmful results that stretch beyond the categories envisioned by classic product liability law.

Design defect analysis typically relies on either the consumer expectation test or the risk-utility balancing test. Neither translates neatly to AI. Ordinary users cannot reasonably form expectations about algorithmic behavior, rendering the first test ill-suited. Risk-utility balancing, meanwhile, demands a weighing of benefits and risks that is complicated by the dynamic nature of AI, where risks may only surface over time or may affect different patient populations in divergent ways.

The learned intermediary doctrine traditionally shields drug manufacturers from direct liability by placing the duty to warn on physicians rather than patients. AI unsettles this principle. Physicians may lack the technical expertise to meaningfully interpret algorithmic risks, weakening their ability to serve as effective intermediaries. When an AI system generates recommendations that even trained professionals cannot fully assess, the rationale for the doctrine begins to erode.

Nor can AI systems easily find refuge in the Communications Decency Act. Section 230 grants broad immunity to online platforms that merely host third-party content, but courts have consistently denied that protection to entities exercising editorial control. Healthcare AI, by its very nature, involves clinical oversight, tailored deployment, and active integration into care delivery. These features place it squarely outside the reach of Section 230, ensuring that liability questions cannot be dismissed under the banner of platform neutrality.

D.3. CLINICAL DOCUMENTATION AND INDEPENDENCE REQUIREMENTS

Proper documentation becomes critical for liability protection when AI systems participate in clinical decision-making. Independent professional judgment must be demonstrated through records showing that physicians considered AI recommendations alongside other clinical factors, rather than reflexively adopting algorithmic outputs. This requires documentation of alternative diagnoses considered, rationale for accepting or rejecting AI recommendations, and integration of AI insights with clinical examination findings.

AI model versioning and change tracking creates new documentation requirements. When AI systems update algorithms, modify training data, or adjust parameters, healthcare providers must maintain records linking patient care decisions to specific system versions. This proves particularly challenging for cloud-based AI services that may update continuously without explicit user notification.

Safety case development borrows from aviation and nuclear industries to establish systematic safety arguments for AI system deployment.¹⁷ Healthcare institutions increasingly adopt safety case frameworks documenting AI system validation, risk mitigation strategies, and ongoing monitoring procedures. These documents serve both clinical governance and legal protection purposes by demonstrating systematic attention to patient safety.

Audit trail maintenance requires comprehensive logging of AI system inputs, outputs, and decision points. However, privacy requirements and storage costs create practical limitations on audit trail completeness. Legal standards for audit trail sufficiency remain undefined, creating uncertainty about documentation requirements necessary for liability protection.

In practice, the standard of care requires documenting the intended use of the system, the validated model version, pediatric subgroup performance, and the rationale for acceptance or override of AI recommendations. Drift alerts must be linked to escalation

¹⁷ Leveson, Nancy G., and John P. Thomas. "STPA Handbook." MIT Partnership for Systems Approaches to Safety (2018).

protocols, and patient disclosure should make clear that AI contributed to the clinical decision.

D.4. EMERGING JURISPRUDENTIAL PATTERNS

Early court decisions involving AI medical devices reveal several emerging patterns that will likely influence future liability allocation. *Loomis v. Wisconsin* addressed algorithmic transparency in criminal justice. While not a healthcare case, it illustrates how courts may tolerate limited algorithmic disclosure when human decision-makers remain involved, offering an analogy for medical AI.¹⁸ The court recognized that due process does not require complete algorithmic transparency, provided that human decision-makers can consider algorithmic limitations and alternative information sources.

Early case law and adjacent domains suggest how courts may allocate responsibility in semi-autonomous contexts. Decisions that distinguish assistance from automation indicate that tools supporting human judgment are typically evaluated under professional-negligence doctrines, whereas more autonomous functions invite product-liability scrutiny focused on design, warnings, and post-market monitoring. In healthcare, this maps onto a divide between recommendation-oriented AI and systems that execute diagnostic or therapeutic actions with limited human oversight.¹⁹

Carpenter v. United States, though centered on location data, reinforced heightened privacy expectations for sensitive information. By analogy, similar reasoning could shape consent and privacy standards for health data processed by AI systems, especially in pediatrics.²⁰ This precedent may influence informed consent requirements for AI systems that process extensive patient data, particularly in pediatric contexts where long-term privacy implications are significant.

State courts have begun addressing medical AI liability through traditional malpractice frameworks while acknowledging the need for new approaches. Legal scholars have identified emerging liability scenarios where AI diagnostic systems allegedly failed to detect pediatric conditions, raising questions about standard of care when AI systems are

¹⁸ *Loomis v. Wisconsin*, 371 Wis. 2d 235, 881 N.W.2d 749 (2016).

¹⁹ *Benavides v. Tesla, Inc.*, No. 21-cv-21940-BB (S.D. Fla. jury verdict Aug. 1, 2025) (post-trial motions pending) (ADAS verdict used here by analogy, not as medical-AI precedent).

²⁰ *Carpenter v. United States*, 138 S. Ct. 2206 (2018).

available but not used, and liability allocation between physicians, hospitals, and AI developers when systems are employed but fail.

The legal landscape continues evolving as more AI-related healthcare cases reach courts. However, current trends suggest that courts will apply existing legal frameworks while developing new doctrines to address AI-specific challenges, rather than creating entirely novel liability theories. This evolutionary approach preserves legal predictability while accommodating technological innovation, though it may leave gaps in protection for patients harmed by AI system failures that do not fit traditional liability categories.

E. PRIVACY, SECURITY, AND DATA GOVERNANCE

Beyond the liability considerations inherent in AI-assisted care, the integration of healthcare AI raises critical privacy and data governance challenges, particularly in safeguarding sensitive pediatric information under federal and state regulations. HIPAA and HITECH requirements intersect with institutional policies and data-sharing arrangements to create complex compliance obligations that must accommodate both AI development needs and patient privacy protections. De-identification limitations, data minimization principles, provenance tracking, role-based access controls, encryption standards, audit logging requirements, and incident response procedures all require adaptation for AI-specific risks and capabilities.

The challenge lies in enabling beneficial innovation while maintaining robust patient safeguards and regulatory compliance across dynamic systems that process vast datasets in ways that traditional privacy frameworks were not designed to address.

E.1. HIPAA BOUNDARIES IN AI TRAINING AND DEPLOYMENT

The application of HIPAA to AI systems reveals fundamental tensions between privacy protection and technological advancement. Protected Health Information includes individually identifiable health information in any form, creating broad coverage that encompasses virtually all data used in healthcare AI development. However, HIPAA's de-identification safe harbor provisions, designed for traditional healthcare uses, prove inadequate for machine learning applications that can re-identify patients through pattern recognition and data correlation.

Research exemptions under HIPAA allow limited PHI use for research purposes, but AI development occupies an ambiguous space between research and commercial product development. Many AI systems begin as research projects but transition to commercial deployment, creating compliance uncertainty about when research protections end and commercial obligations begin. Institutional Review Board approval requirements may apply to AI development using human subjects data, but IRB expertise in AI evaluation remains limited.

Business Associate Agreements require careful drafting to address AI-specific risks. Traditional BAAs contemplate defined uses and disclosures of PHI, but machine learning systems may identify unexpected patterns or correlations that extend beyond originally anticipated uses. Cloud-based AI services present additional challenges because data may be processed across multiple geographic locations and infrastructure providers, each requiring appropriate contractual protections.

Minimum necessary requirements conflict with AI systems' data requirements. Machine learning algorithms often perform better with larger, more comprehensive datasets, while HIPAA requires limiting PHI access to the minimum necessary for intended purposes. This tension becomes acute in pediatric applications where rare conditions require extensive data sharing to achieve statistical significance for training algorithms.

E.2. VENDOR RISK MANAGEMENT AND CLINICAL SBOMS

Software Bill of Materials requirements, inspired by supply chain security frameworks, are emerging as essential tools for healthcare AI governance.²¹ Clinical SBOMs must identify all software components, including training datasets, algorithm libraries, and infrastructure dependencies used in AI systems. This visibility enables vulnerability management and compliance verification but creates new administrative burdens for healthcare institutions.

Vendor risk assessment for AI systems requires evaluating technical capabilities alongside traditional business factors. Healthcare organizations must assess algorithm validation methodologies, bias testing procedures, and ongoing monitoring capabilities of AI vendors. Multi-vendor integration risks emerge when AI systems from different

²¹ Executive Order 14028, "Improving the Nation's Cybersecurity," 86 Fed. Reg. 26633 (May 12, 2021).

developers interact within healthcare ecosystems, potentially creating unexpected behaviors or security vulnerabilities.

Data residency and sovereignty requirements vary by jurisdiction and may conflict with AI system architectures that rely on distributed computing resources. European GDPR requirements, applicable to EU patient data regardless of processing location, create compliance obligations that extend beyond U.S. healthcare institutions to their AI vendors and cloud providers.²² State privacy laws, such as the California Consumer Privacy Act, add additional layers of complexity for healthcare AI systems serving diverse patient populations.

Third-party risk management extends beyond direct AI vendors to include training data providers, cloud infrastructure companies, and integration partners. Each relationship in the AI supply chain presents potential privacy and security risks that healthcare institutions must identify, assess, and mitigate through appropriate contractual and technical controls.

E.3. DATA MINIMIZATION VERSUS LEARNING OPTIMIZATION

Purpose limitation principles require that data collection and use align with specified, legitimate purposes. AI systems challenge these principles because machine learning can identify patterns and relationships that were not anticipated during initial data collection. A pediatric growth monitoring AI might discover correlations between growth patterns and future health risks that extend beyond the original monitoring purpose, raising questions about appropriate use of these insights.

Storage limitation requirements mandate that personal data be kept only as long as necessary for processing purposes. AI systems complicate this principle because model training may require extended data retention, while the resulting models can make predictions without retaining original training data. However, model retraining, bias correction, and performance monitoring may require access to historical data, creating tension with deletion requirements.

²² General Data Protection Regulation (GDPR), Regulation (EU) 2016/679, Art. 3 (territorial scope).

Data quality and accuracy obligations take on new meaning in AI contexts. Training data quality directly affects algorithm performance and fairness, making data accuracy both a privacy and patient safety issue. Right to rectification under various privacy laws allows individuals to correct inaccurate personal data, but correcting training data in deployed AI models may require expensive retraining processes that organizations resist.

Consent mechanisms can be insufficient for AI applications that process data in ways individuals cannot reasonably anticipate or understand. Dynamic consent frameworks attempt to address this challenge by allowing granular, ongoing consent management, but implementation complexity and user burden limit practical adoption. For pediatric populations, consent complexity increases because parents provide initial authorization while children may later seek to modify or withdraw consent as they mature.

In pediatric contexts, transparency obligations extend not only to patients but also to parents or guardians, raising distinctive questions about how algorithmic reasoning is communicated to non-specialist caregivers.

E.4. ALGORITHMIC IMPACT ASSESSMENT FRAMEWORKS

Privacy Impact Assessments systematically evaluate privacy risks associated with new technologies and processes. In healthcare AI, these assessments require enhanced frameworks to address algorithmic bias, the effects of automated decision-making, and long-term privacy implications. Algorithmic Impact Assessments extend beyond privacy to evaluate fairness, accountability, and transparency concerns specific to AI systems, ensuring that healthcare organizations can identify and mitigate risks introduced by complex algorithms.

Data Protection Impact Assessments, mandated by GDPR for high-risk processing activities, offer a robust framework that healthcare organizations increasingly adopt for AI systems, even in jurisdictions where they are not legally required. These assessments must evaluate potential impacts on vulnerable populations, such as pediatric patients, whose unique needs demand specialized considerations. Effective DPIAs for healthcare AI analyze risks related to data scarcity, developmental variability, and informed consent, while also assessing the adequacy of mitigation measures to protect patient rights and safety.

Continuous monitoring requirements account for the dynamic nature of AI systems, which may evolve in behavior as they process new data and update algorithms. Unlike traditional privacy assessments conducted once at deployment, AI systems necessitate ongoing evaluation to detect privacy violations, bias amplification, or performance degradation over time. This continuous oversight poses resource challenges for healthcare institutions, particularly those lacking specialized expertise in AI evaluation, necessitating investment in training and infrastructure to ensure compliance.

Transparency reporting mechanisms enable healthcare organizations to communicate AI use policies, performance metrics, and decision-making processes to patients, regulators, and the public. Effective transparency fosters trust and accountability but requires balancing clinical accountability with technical complexity and competitive interests. Healthcare organizations must ensure that transparency reports provide clear, accessible information while protecting proprietary system details and maintaining compliance with regulatory standards.

A critical aspect of transparency is its distinction from explainability. Transparency involves open access to model architecture, training data, and algorithmic processes, allowing regulators and clinicians to verify system design. Explainability requires providing comprehensible reasons for specific AI decisions, enabling physicians to evaluate recommendations effectively. The “black box problem” occurs when AI systems operate through decision pathways that defy human comprehension, creating scenarios where a system may be transparent through documented processes yet inexplicable if its logic exceeds human cognitive capacity, or explainable through simplified post-hoc rationalizations that obscure proprietary details. In pediatric contexts, where trust and informed consent are critical, transparency and explainability must deliver clinically meaningful information through age-appropriate communication and parental information rights without compromising patient safety or intellectual property. Algorithmic Impact Assessments should incorporate metrics to evaluate both transparency and explainability, ensuring compliance with regulatory and clinical obligations.

Vulnerability response procedures must address technical vulnerabilities and privacy breaches unique to AI systems. Traditional incident response protocols may be inadequate for AI-related incidents, such as subtle bias introduction, adversarial attacks, or gradual

performance degradation. Healthcare organizations require specialized response capabilities that integrate cybersecurity, privacy protection, and clinical safety expertise to effectively manage AI-specific threats and maintain patient trust and safety.

F. FAIRNESS AND NON-DISCRIMINATION

Fairness and non-discrimination in healthcare AI constitute core quality and compliance imperatives that extend beyond technical performance metrics to encompass fundamental civil rights obligations. Bias sources emerge throughout AI system development and deployment, from training data composition and labeling practices to model drift patterns and implementation contexts that can produce disparate outcomes across clinically meaningful subgroups. Healthcare institutions must establish operational controls to measure, monitor, and mitigate discriminatory performance while maintaining clinical effectiveness and regulatory compliance.

Legal obligations prohibiting healthcare discrimination intersect with technical bias evaluation methods to create complex accountability frameworks that require systematic documentation, threshold establishment, and independent review processes. The challenge intensifies in pediatric contexts where developmental factors, family dynamics, and long-term outcome implications compound traditional demographic vulnerability patterns in ways that existing fairness metrics may inadequately capture.

F.1. DOCUMENTED CASES OF ALGORITHMIC DISCRIMINATION

Healthcare AI systems have demonstrated concerning patterns of bias that perpetuate and amplify existing healthcare disparities. The Optum algorithm case revealed systematic racial bias in a widely-used healthcare risk prediction system that underestimated care needs for Black patients by systematically correlating health costs with health needs, despite cost differences reflecting access disparities rather than actual health status.²³ This case established that facially neutral algorithms could violate civil rights laws through disparate impact, even without intentional discrimination.

IBM Watson for Oncology faced criticism for training primarily on data from Memorial Sloan Kettering Cancer Center, resulting in treatment recommendations that reflected the

²³ Obermeyer, Ziad, et al. "Dissecting Racial Bias in an Algorithm Used to Manage the Health of Populations." *Science* 366, no. 6464 (2019): 447-453.

demographic and socioeconomic characteristics of that institution's patient population.²⁴ When deployed in diverse healthcare settings globally, Watson's recommendations often proved inappropriate for different patient populations, highlighting how training data limitations can create systematic bias.

Babylon Health's AI chatbot demonstrated gender bias in symptom assessment, systematically underestimating women's cardiac risks while over-pathologizing men's mental health concerns. These patterns reflected historical healthcare biases embedded in training data and clinical protocols, showing how AI systems can perpetuate discrimination patterns that human clinicians are increasingly trained to recognize and correct.²⁵

Pediatric AI systems face unique bias challenges because training data limitations interact with developmental, genetic, and social factors that vary across populations. Sepsis prediction algorithms trained primarily on data from tertiary care centers may perform poorly in community hospital settings where patient populations, resource availability, and clinical workflows differ significantly from training environments.

Pediatric datasets are especially vulnerable to bias because of their smaller size and overrepresentation of tertiary-care populations, which may not reflect broader child health realities.

F.2. CIVIL RIGHTS AND HEALTHCARE ACCESS OBLIGATIONS

Section 1557 of the Affordable Care Act prohibits discrimination based on race, color, national origin, sex, age, or disability in healthcare programs receiving federal financial assistance.²⁶ This broad coverage encompasses most healthcare institutions and extends to AI systems used in these settings. The law's disparate impact theory allows discrimination challenges even when algorithms appear facially neutral but produce discriminatory effects.

²⁴ Ross, Casey, and Ike Swetlitz. "IBM pitched Watson as a revolution in cancer care. It's nowhere close." STAT News, September 5, 2017.

²⁵ Fraser, Hamish, et al. "Safety of Patient-facing Digital Symptom Checkers." *The Lancet* 392, no. 10161 (2018): 2263-2264.

²⁶ 42 U.S.C. § 18116 (Section 1557 of the Affordable Care Act).

Americans with Disabilities Act requirements apply to healthcare AI systems that must provide effective communication and equal access for individuals with disabilities.²⁷ Voice-based AI systems must accommodate hearing impairments, while visual AI interfaces must support vision disabilities. Pediatric AI systems must consider developmental disabilities and age-appropriate communication methods.

Title VI of the Civil Rights Act requires that federally funded healthcare programs provide meaningful access for individuals with limited English proficiency.²⁸ AI systems serving diverse populations must incorporate multilingual capabilities and cultural competency considerations. Training data must reflect linguistic and cultural diversity to avoid systematic bias against non-English speaking populations.

Section 504 of the Rehabilitation Act prohibits disability discrimination in federal programs and requires reasonable accommodations for individuals with disabilities.²⁹ Healthcare AI systems must be designed and implemented in ways that do not systematically disadvantage individuals with disabilities, either through direct exclusion or through use of proxies that correlate with disability status.

F.3. BIAS AUDITING AND FAIRNESS METRICS

Statistical parity requires that AI system outputs distribute equally across demographic groups. However, this metric may conflict with medical accuracy goals when underlying health risks vary across populations. For example, certain genetic conditions occur more frequently in specific ethnic groups, making statistical parity potentially harmful if it prevents appropriate risk assessment and intervention.

Equalized odds measures require equal true positive and false negative rates across groups, focusing on predictive accuracy rather than outcome distribution. This metric better aligns with medical goals but may still reflect underlying healthcare access disparities that confound the relationship between risk factors and outcomes.

Demographic parity ensures that positive predictions occur at equal rates across groups, while equality of opportunity focuses on equal true positive rates for individuals who

²⁷ Americans with Disabilities Act, 42 U.S.C. §§ 12101-12213 (1990).

²⁸ Title VI of the Civil Rights Act of 1964, 42 U.S.C. § 2000d.

²⁹ Section 504 of the Rehabilitation Act of 1973, 29 U.S.C. § 794.

should receive positive predictions. The choice of fairness metrics significantly impacts AI system behavior and requires clinical context-specific evaluation rather than universal application.

Individual fairness approaches evaluate whether similar individuals receive similar predictions, avoiding group-level metrics that may obscure individual discrimination. However, defining similarity in medical contexts requires careful consideration of clinically relevant factors versus protected characteristics that should not influence treatment decisions.

Intersectionality analysis examines how multiple identity characteristics interact to create unique bias patterns. Pediatric populations present particular intersectionality challenges because age intersects with other demographic factors in ways that may compound discrimination. Young women of color, for example, may face cumulative bias from gender, race, and age factors in AI-driven care recommendations.

F.4. CONSTITUTIONAL AND REGULATORY CONSTRAINTS

Equal Protection Clause analysis applies strict scrutiny to government actions that discriminate based on race or ethnicity, intermediate scrutiny for gender discrimination, and rational basis review for other classifications. Public healthcare institutions using AI systems must ensure that algorithmic decisions can survive appropriate constitutional scrutiny based on the affected groups and interests involved.

Due Process requirements may apply to AI systems that significantly impact patient care decisions, particularly in public healthcare settings. Procedural due process might require notice of AI system use, opportunity to challenge algorithmic recommendations, and access to meaningful human review of automated decisions affecting patient care.

NIST AI Risk Management Framework provides voluntary guidelines for AI bias assessment and mitigation that many healthcare organizations adopt as industry best practices.³⁰ The framework emphasizes continuous monitoring, stakeholder engagement, and documentation requirements that align with legal compliance needs while promoting responsible AI development and deployment.

³⁰ NIST, AI Risk Management Framework (AI RMF 1.0), NIST AI 100-1, at 47-52 (2023).

State algorithmic accountability laws vary significantly in scope and requirements but generally mandate bias testing, transparency reporting, and impact assessment for automated decision-making systems. New York City Local Law 144 requires bias audits for automated employment decision tools and may serve as a model for healthcare AI regulation.³¹

HHS AI guidance emphasizes the importance of bias testing and mitigation in healthcare AI systems, particularly those serving vulnerable populations.³² The guidance recommends multi-stakeholder engagement, including affected communities, in AI system design and evaluation processes to identify and address potential discrimination before deployment.

F.5. INSURANCE AND COVERAGE IMPLICATIONS

Actuarial fairness principles in insurance pricing may conflict with anti-discrimination requirements when AI systems identify new risk factors that correlate with protected characteristics. Health insurance regulations generally prohibit discrimination based on protected characteristics but allow risk-based pricing for factors considered actuarially justified.

Genetic Information Nondiscrimination Act prohibits health insurance and employment discrimination based on genetic information.³³ AI systems that identify genetic risk factors or use genetic proxies in predictions must comply with GINA requirements, which may limit the use of certain algorithmic insights in insurance coverage decisions.

Pre-existing condition protections under the Affordable Care Act prohibit health insurance discrimination based on health status.³⁴ However, AI systems that predict future health risks may identify individuals likely to develop expensive conditions, creating tension between algorithmic insights and coverage protection requirements.

Medicaid and Medicare coverage decisions increasingly rely on AI systems for fraud detection, utilization review, and care management. These systems must comply with

³¹ New York City Local Law 144 of 2021, N.Y.C. Admin. Code § 20-870 (2023).

³² HHS Office for Civil Rights, “Algorithmic Bias in Healthcare: Key Civil Rights Concerns and Potential Solutions” (2022).

³³ Genetic Information Nondiscrimination Act (GINA), 42 U.S.C. §§ 2000ff to 2000ff-11 (2008).

³⁴ Patient Protection and Affordable Care Act § 2704, 42 U.S.C. § 300gg-3 (2010).

civil rights requirements and avoid discriminatory impacts on protected populations. Medicare Advantage risk adjustment uses algorithmic methods that have faced scrutiny for potential bias against certain demographic groups.

The intersection of AI capabilities with insurance regulation creates ongoing challenges as algorithms become more sophisticated at-risk prediction while legal frameworks struggle to balance actuarial accuracy with anti-discrimination principles. This tension becomes particularly pronounced in pediatric contexts where long-term risk predictions may create lifelong coverage implications based on childhood health data.

G. ARTIFICIAL INTELLIGENCE IN PEDIATRIC CARE: SPECIAL CONSIDERATIONS

Pediatric healthcare presents unique challenges for AI implementation that extend far beyond simple population scaling or parameter adjustment. Developmental trajectories, consent and assent frameworks, family-centered care models, and long-term outcome implications require fundamentally different approaches to AI system design, validation, and governance. Data strategies must accommodate scarce and rapidly evolving patient populations, while validation protocols require calibration to age-specific physiological and behavioral patterns that change continuously throughout childhood and adolescence.

Legal frameworks developed for adult healthcare prove inadequate for pediatric AI applications, where parental authority intersects with emerging adolescent autonomy, long-term privacy implications extend decades into the future, and consent mechanisms must account for developmental capacity limitations. Human oversight and escalation protocols must integrate family-centered decision-making processes while maintaining clinical effectiveness and safety standards appropriate for vulnerable populations whose medical decisions carry lifelong consequences.

Documentation requirements in pediatric AI contexts must capture not only immediate clinical rationale but also developmental appropriateness assessments, family involvement in decision-making, and longitudinal follow-up considerations that may not emerge until years after initial AI-assisted interventions. The intersection of childhood vulnerability, technological complexity, and family dynamics creates governance challenges that existing regulatory frameworks address only superficially.

G.1. TECHNICAL CHALLENGES UNIQUE TO PEDIATRIC POPULATIONS

Data scarcity versus precision demands creates the central paradox of pediatric AI development. Children represent approximately 22% of the U.S. population but exhibit exponentially greater physiological variability due to rapid growth, developmental changes, and maturation processes. This scarcity becomes acute for rare pediatric conditions, where patient cohorts often number in mere hundreds. Combined with age-related variability and limited representation in clinical datasets, this renders traditional machine learning approaches statistically fragile and clinically unreliable without pediatric-specific calibration.³⁵ As early as the twentieth century, it was argued that children should be recognized as full persons with distinct rights and needs rather than incomplete adults, a perspective that modern AI design must translate into age-stratified modeling.³⁶

Developmental heterogeneity challenges AI systems designed around adult physiological assumptions. A cardiac AI system trained on adult ECG patterns may misinterpret normal pediatric heart rhythms as pathological, while growth prediction algorithms must account for genetic variation, nutritional status, and hormonal influences that vary dramatically across childhood development stages. Age-stratified modeling approaches attempt to address this challenge by creating separate algorithms for different pediatric age groups, but these further fragments already limited training datasets.

Transfer learning from adult populations offers a potential solution but introduces systematic bias risks. Adult-trained algorithms may identify patterns that appear in children but carry different clinical significance. For example, biomarker values that predict sepsis in adults may indicate normal physiological stress responses in children, leading to false positive predictions that trigger unnecessary interventions and resource utilization.

Synthetic data generation emerges as a promising approach for addressing pediatric data limitations through computational methods that create artificial patient data maintaining

³⁵ American Academy of Pediatrics Committee on Bioethics. "Informed Consent in Decision-Making in Pediatric Practice." *Pediatrics* 138, no. 2 (2016): e20161484.

³⁶ Korczak, Janusz. "How to Love a Child". Warsaw: Nasza Księgarnia, 1920 (English translation: New York: Farrar, Straus and Giroux, 2007).

statistical properties of real populations while preserving privacy.³⁷ However, synthetic pediatric data must accurately model complex developmental trajectories and rare condition presentations, requiring sophisticated generative models that remain largely experimental in clinical applications.

Federated learning architectures allow multiple pediatric institutions to collaboratively train AI models without sharing patient data directly.³⁸ This approach addresses privacy concerns while aggregating knowledge across institutions, but requires standardized data formats, compatible technical infrastructure, and legal frameworks for inter-institutional collaboration that remain under development.

G.2. LEGAL FRAMEWORK SPECIFICITIES FOR MINORS

Parental permission versus child assent creates complex consent scenarios when AI systems affect pediatric care decisions. The American Academy of Pediatrics guidelines distinguish between parental permission for medical interventions and child assent for participation in research or novel treatments.³⁹ AI-assisted diagnosis typically requires only parental permission, but experimental AI systems or those with significant uncertainty may require age-appropriate child assent processes.

Mature minor doctrines vary by state and medical context, allowing adolescents to make independent healthcare decisions in specific circumstances. State laws vary significantly in recognizing mature minor capacity for healthcare decisions, with jurisdictions applying different standards for determining when adolescents can consent independently to medical care. Mental health AI systems, reproductive health applications, and substance abuse treatment tools may involve adolescent patients who can consent independently, potentially excluding parents from AI-generated insights that traditional care coordination would include. This perspective echoes the Charter of the Rights of the Hospitalized Child (1986), which emphasized that children must be treated as rights-bearing individuals in medical contexts.⁴⁰

³⁷ Chen, Richard J., et al. "Synthetic Data in Machine Learning for Medicine and Healthcare." *Nature Biomedical Engineering* 5, no. 6 (2021): 493-497.

³⁸ Li, Tian, et al. "Federated Learning: Challenges, Methods, and Future Directions." *IEEE Signal Processing Magazine* 37, no. 3 (2020): 50-60.

³⁹ AAP Committee on Bioethics. "Informed Consent in Decision-Making in Pediatric Practice," at e20161485.

⁴⁰ Exeni, Ramón A., "Carta de los Derechos del Niño Hospitalizado" (Buenos Aires, 1986).

Emancipated minor status further complicates consent frameworks when adolescents gain legal independence through marriage, military service, or court order. AI systems must accommodate these legal variations while maintaining appropriate clinical oversight and safety protections that recognize adolescents' continuing developmental needs regardless of legal status.

COPPA compliance becomes relevant when pediatric AI systems include interactive components, educational games, or patient portal access.⁴¹ COPPA requires verifiable parental consent for data collection from children under 13, but medical necessity may justify data processing without full COPPA compliance under healthcare-specific exemptions that remain legally untested.

Long-term data implications present unique challenges for pediatric AI applications because childhood data may have lifelong significance. Genetic risk predictions, developmental assessments, and behavioral health evaluations conducted in childhood could influence education, employment, and insurance decisions decades later. Legal frameworks must balance immediate clinical benefits with long-term privacy protection for individuals who cannot fully understand future implications of current data use.

G.3. CURRENT PEDIATRIC AI APPLICATIONS AND OUTCOMES

Rare disease diagnosis represents one of the most successful pediatric AI applications. Face2Gene uses facial recognition algorithms to identify genetic syndromes, demonstrating particular effectiveness for conditions with distinctive facial features.⁴² The system has contributed to diagnoses for thousands of children with rare conditions, often identifying syndromes that human clinicians missed or required extensive specialist consultation to recognize.

Neonatal sepsis prediction through systems like EPIC's predictive model and RAVEN demonstrates significant promise for improving outcomes in vulnerable newborn populations.⁴³ These systems analyze vital signs, laboratory values, and clinical observations to identify sepsis risk hours before human recognition, enabling earlier

⁴¹ 15 U.S.C. § 6501(1) (COPPA definition of “child”).

⁴² Gurovich, Yaron, et al. “Identifying Facial Phenotypes of Genetic Disorders Using Deep Learning.” *Nature Medicine* 25, no. 1 (2019): 60-64.

⁴³ Kamaleswaran, Rishikesan, et al. “A Robust Deep Learning Approach for Automatic Sepsis Prediction in the ICU.” *Journal of the American Medical Informatics Association* 25, no. 11 (2018): 1485-1492.

intervention that can be life-saving in neonatal contexts. Real-world experiences with the deployment of deep learning sepsis models have shown that extensive workflow alignment and clinician acceptance are as critical as predictive accuracy for ensuring safety and effectiveness.⁴⁴

Application	Purpose	Key Metrics	Source	Notes
Face2Gene	Rare disease diagnosis (genetic syndromes)	Sensitivity: ~90%, Specificity: ~85%, AUC: ~0.92	Gurovich et al., Nature Medicine (2019)	Effective for syndromes with facial phenotypes; limited by training data diversity.
Epic Sepsis Model	Neonatal sepsis prediction	AUC: 0.63, True Positive Rate: ~7% (missed cases), Alert Burden: ~18% of inpatients	Wong et al., JAMA Internal Medicine (2021)	Poor generalization across institutions; high alert fatigue risk.
Cognoa	Autism spectrum disorder screening	Sensitivity: ~80%, Specificity: ~75%, PPV: ~70%	Dawson et al., Scientific Reports (2018)	Enables early screening in primary care; requires family-provided video data.
RAVEN	Neonatal sepsis prediction	Sensitivity: ~85%, Specificity: ~80%, AUC: ~0.87	Kamaleswaran et al., JAMIA (2018)	Strong performance in ICU settings; limited external validation.
Congenital Heart Disease AI	Fetal ultrasound/echocardiogram analysis	Sensitivity: ~95%, Specificity: ~90%, AUC: ~0.94	Arnaout et al., Nature Medicine (2021)	High accuracy in resource-limited settings; needs broader population testing.

Notes:
 Metrics are derived from cited studies where available; some values (e.g., Cognoa PPV) are estimated based on reported performance ranges.
 AUC: Area Under the Receiver Operating Characteristic Curve; PPV: Positive Predictive Value.
 All applications require ongoing validation to address pediatric data scarcity and developmental variability.

Autism spectrum disorder screening through AI analysis of behavioral videos, eye-tracking data, and developmental assessments offers potential for earlier diagnosis and intervention.⁴⁵ Systems like Cognoa's pediatric behavioral health platform analyze home videos to identify autism markers, enabling screening in primary care settings without specialist referral delays that often postpone diagnosis by months or years.

Growth and development monitoring leverages AI to identify deviation from normal developmental trajectories that might indicate underlying conditions requiring

⁴⁴ Sendak, Mark, et al., "Real-World Integration of a Sepsis Deep Learning Technology," *NPJ Digital Medicine* 3, no. 143 (2020). DOI: 10.1038/s41746-020-00347-2.
⁴⁵ Dawson, Geraldine, et al. "Atypical Postural Control Can Be Detected via Computer Vision Analysis in Toddlers with Autism Spectrum Disorder." *Scientific Reports* 8, no. 1 (2018): 17008.

intervention. Pediatric growth AI systems can identify endocrine disorders, nutritional deficiencies, and genetic conditions through growth pattern analysis that surpasses traditional percentile charts in sensitivity and specificity.

Congenital heart disease diagnosis benefits from AI systems that analyze fetal ultrasounds, newborn echocardiograms, and chest X-rays to identify structural abnormalities.⁴⁶ These applications prove particularly valuable in resource-limited settings where pediatric cardiology expertise is scarce, enabling earlier recognition and referral for life-saving interventions.

Despite the scarcity of pediatric data, as previously discussed, applications like Face2Gene and Cognoa demonstrate success through innovative techniques such as transfer learning from adult datasets and family-centered care requirements, though ongoing validation is essential to address developmental variability.⁴⁷

Sendak and colleagues, however, documented that real-world integration of a sepsis deep learning model required extensive workflow alignment and clinician acceptance, underscoring that implementation challenges remain as critical as predictive accuracy.

G.4. PEDIATRIC-SPECIFIC ETHICAL CONSIDERATIONS

Best interests versus autonomy creates tension when AI systems generate recommendations that conflict with family preferences or cultural values. The pediatric best interests standard requires decisions that maximize child welfare, but AI systems may identify optimal treatments that families refuse based on religious beliefs, cultural practices, or quality of life considerations that algorithms cannot adequately weigh. Even very young children possess a voice that must be heard in clinical contexts, reinforcing the ethical imperative of incorporating child assent into pediatric AI-assisted care.⁴⁸

Long-term predictions and stigmatization pose unique risks when AI systems identify children at risk for future conditions that may never develop. Predictions of autism risk, learning disabilities, or mental health conditions could influence educational placement,

⁴⁶ Arnaout, Rima, et al. "An Ensemble of Neural Networks Provides Expert-level Prenatal Detection of Complex Congenital Heart Disease." *Nature Medicine* 27, no. 5 (2021): 882-891.

⁴⁷ Burns et al., "Pediatric Clinical Decision Support Systems: A Systematic Review and Meta-analysis," *JAMA Pediatrics* 174, no. 12 (2020): 1184-1194.

⁴⁸ Dolto, Françoise. "The Case of the Child: The Child as a Subject". Paris: Éditions du Seuil, 1985 (English translation: London: Karnac, 1988).

social interactions, and family dynamics in ways that create self-fulfilling prophecies or unnecessary anxiety and discrimination.

Family system impacts require consideration because pediatric AI recommendations affect not just individual patients but entire family units. An AI system that predicts genetic risk may have implications for siblings, parents, and extended family members who did not consent to genetic evaluation but become subject to its results through family relationships.

Developmental capacity considerations recognize that children's decision-making abilities, risk comprehension, and future-oriented thinking continue developing throughout childhood and adolescence. AI systems that make recommendations with long-term implications must account for developmental limitations in understanding consequences and expressing preferences about future outcomes.

School and social integration concerns arise when AI-generated diagnoses or predictions influence educational placement, social services involvement, or peer relationships. Confidentiality protections must balance clinical benefits with potential social stigmatization, particularly for mental health, behavioral, or developmental condition predictions that could affect academic and social opportunities.

G.5. PROPOSED PEDIATRIC AI SAFETY FRAMEWORK

Evidence thresholds for pediatric deployment should require higher validation standards than adult AI systems due to developmental considerations and long-term outcome implications. Pediatric AI safety cases must demonstrate effectiveness across age groups, developmental stages, and diverse pediatric populations while establishing appropriate uncertainty thresholds that trigger human oversight or system limitation.

Age-stratified validation requirements should mandate separate testing for neonates, infants, children, and adolescents rather than treating pediatric populations as homogeneous. Each age group presents distinct physiological characteristics, data patterns, and clinical contexts that require separate validation to ensure safety and effectiveness.

Developmental milestone integration should incorporate normal child development knowledge into AI system design and evaluation. Systems must distinguish between developmental variations and pathological conditions, requiring collaboration between AI developers and pediatric development experts during system design and validation phases.

Family-centered design principles should ensure that AI systems support family involvement in pediatric care while respecting appropriate boundaries for adolescent privacy and autonomy. Interface design, information sharing, and decision support features must accommodate family dynamics while maintaining focus on child welfare as the primary consideration.

Long-term outcome monitoring requirements should extend beyond traditional post-market surveillance to track developmental outcomes, educational impacts, and social consequences of AI-assisted pediatric care decisions. This monitoring must continue across childhood and into adulthood to capture delayed effects that may not appear in conventional short-term safety assessments.

Specialized oversight requirements should establish pediatric AI review committees with expertise in child development, family dynamics, and pediatric medical ethics. These committees should evaluate AI systems for age-appropriate communication, developmental sensitivity, and family impact considerations that general AI oversight committees may lack expertise to assess adequately.

This specialized framework acknowledges that pediatric AI applications require fundamentally different approaches to validation, oversight, and safety monitoring than adult-focused systems, while providing concrete implementation guidance for healthcare institutions, regulators, and technology developers working in pediatric contexts.

H. CASE STUDIES AND LEGAL PRECEDENTS

To illustrate the practical implications of the pediatric-specific challenges outlined in the preceding section, this section analyzes case studies of AI implementations in healthcare, drawing lessons applicable to both general and pediatric contexts. Each case demonstrates where existing controls succeeded or failed, how professional norms evolved in response

to AI-related incidents, and what operational lessons emerged for documentation, oversight, change control, and stakeholder communication.

Rather than relitigating specific outcomes, these examples distill actionable insights that healthcare institutions, technology developers, and legal practitioners can apply to reduce implementation risks while improving patient care quality. The contrast between failed deployments and successful implementations reveals patterns that predict AI system sustainability and legal risk exposure across diverse clinical contexts.

Performance variations across institutions, workflow integration challenges, regulatory oversight gaps, and liability allocation disputes provide concrete illustrations of theoretical frameworks examined in preceding sections. Documentation deficits, bias manifestations, and consent process failures offer specific guidance for avoiding similar problems in future AI deployments while establishing defensible clinical and legal practices.

H.1. EPIC SYSTEMS SEPSIS ALGORITHM: LESSONS FROM IMPLEMENTATION

The Epic Sepsis Model deployment across hundreds of healthcare systems provides critical insights into real-world AI implementation challenges and legal implications.⁴⁹ Initially lauded for its ability to predict sepsis hours before clinical recognition, subsequent analyses revealed significant performance variations across institutions, patient populations, and clinical contexts that raise fundamental questions about AI system portability and liability allocation.

External validation has shown that performance reported at development sites does not consistently generalize to other institutions with different populations, workflows, and data infrastructure. This variation challenges the traditional medical device paradigm of consistent performance characteristics and raises questions about the adequacy of single-site validation for multi-institutional deployment.

⁴⁹ Wong, Andrew, et al. “External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients.” *JAMA Internal Medicine* 181(8):1065–1070 (2021). DOI: 10.1001/jamainternmed.2021.2626

An external validation at the University of Michigan, covering 38,455 hospitalizations from 2018 to 2019, found that the Epic Sepsis Model showed poor discrimination and calibration. The area under the ROC curve was about 0.63, it captured only around seven percent of sepsis cases that clinicians missed for timely antibiotics, and it triggered alerts for roughly eighteen percent of all inpatients, a volume consistent with alert burden and fatigue. These results highlight portability limits and the need for local revalidation and governance before widescale deployment.

High alert volumes increased workload and created a meaningful risk of alert fatigue, which can undermine responsiveness to genuine cases and contributes to the portability and governance concerns documented in external evaluations.⁵⁰

The deployment of the Epic Sepsis Model also raises questions about liability allocation in AI-assisted clinical decision-making. Variability across institutions, together with alert burden, can shape standard-of-care expectations and responsibility distribution among clinicians, hospitals, and vendors, reinforcing the need for robust validation, transparent documentation, and proactive governance.⁵¹

Documentation challenges revealed gaps in clinical record-keeping practices when AI systems participate in decision-making. Many institutions lacked systematic documentation of AI system recommendations, physician responses, and rationale for accepting or rejecting algorithmic suggestions. This documentation deficit complicates both clinical quality improvement and legal defense when AI-assisted care decisions face scrutiny.

H.2. IBM WATSON FOR ONCOLOGY: PROMISE VERSUS REALITY

The implementation challenges observed in the Epic Sepsis Model find parallels in other high-profile AI deployments, such as IBM Watson for Oncology, which further illustrate the complexities of achieving clinical efficacy and regulatory compliance. Initially heralded for its capacity to deliver expert-level cancer treatment recommendations

⁵⁰ Habib, Anand R.; Lin, Anthony L.; Grant, Richard W. “The Epic Sepsis Model Falls Short—The Importance of External Validation.” *JAMA Internal Medicine* 181(8):1040–1041 (2021). DOI: 10.1001/jamainternmed.2021.3333.

⁵¹ Cohen, I. Glenn; Amarasingham, Ruben; Shah, Anand; Xie, Bin; Lo, Bernard. “The Legal and Ethical Concerns That Arise From Using Complex Predictive Analytics in Health Care.” *Health Affairs* 33(7):1139–1147 (2014). DOI: 10.1377/hlthaff.2014.0048.

through comprehensive literature synthesis and data integration, Watson's widespread adoption was curtailed by significant operational shortcomings and subsequent market withdrawal, offering critical insights into the constraints of AI applications and regulatory oversight.⁵²

The system's reliance on training data from Memorial Sloan Kettering Cancer Center introduced biases that limited its applicability across diverse healthcare contexts. When implemented internationally, Watson's outputs frequently misaligned with local patient demographics, treatment protocols, and resource availability, revealing the critical need for broadly representative datasets to ensure generalizability in varied clinical environments.⁵³

Beyond data challenges, regulatory gaps exacerbated Watson's shortcomings, as its classification as a clinical decision support tool exempted it from rigorous FDA scrutiny, potentially delaying the identification of performance deficiencies. This case contributed to calls for enhanced regulatory scrutiny of AI-based decision support systems, emphasizing the need for robust evaluation prior to widespread adoption.⁵⁴

These operational shortcomings raise significant legal considerations regarding responsibility in AI-assisted care. Reports have documented instances where Watson's suggestions deviated from clinical standards, potentially leading to suboptimal treatment decisions. While no malpractice litigation has been publicly documented, these discrepancies highlight the necessity for rigorous validation, transparent performance metrics, and clear protocols to delineate accountability among clinicians, institutions, and technology vendors, ensuring that AI outputs enhance rather than undermine patient outcomes.⁵⁵

H.3. BABYLON HEALTH CHATBOT: REGULATORY RESPONSE AND LIABILITY

⁵² Ross, Casey, and Ike Swetlitz. "IBM pitched Watson as a revolution in cancer care. It's nowhere close." STAT News, September 5, 2017.

⁵³ Lee, J., et al., "The challenges of implementing AI in global healthcare: Lessons from Watson for Oncology," *Journal of Medical Systems* 42, no. 10 (2018): 187.

⁵⁴ Food and Drug Administration, "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations," FDA-2024-D-4488 (2025).

⁵⁵ Somashekhar et al., "Watson for Oncology and breast cancer treatment recommendations: Agreement with physicians," *Journal of Clinical Oncology* 36, no. 15_suppl (2018): e18595.

Similar to the clinical integration challenges faced by IBM Watson for Oncology, consumer-facing AI systems like Babylon Health's chatbot highlight additional complexities in regulatory compliance and accountability, particularly when interacting directly with patients, including pediatric populations. Marketed as a triage mechanism capable of assessing symptoms and guiding care pathways, the chatbot faced scrutiny for variable diagnostic accuracy, prompting concerns about its safety and appropriate classification under medical device regulations.⁵⁶

Studies comparing the chatbot's performance to human clinicians revealed inconsistent outcomes across medical conditions, with early claims of equivalence to general practitioners undermined by missed diagnoses for serious disorders, such as cardiovascular and neurological conditions. These findings triggered investigations by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Care Quality Commission (CQC), which questioned whether the chatbot's functionality warranted designation as a regulated medical device.⁵⁷

Operating in a regulatory gray area between clinical decision support and direct patient engagement, the chatbot raised compliance issues, particularly in the U.S. context. Its interaction with pediatric populations through mobile applications prompted questions about adherence to the Children's Online Privacy Protection Act (COPPA), especially regarding parental consent and data minimization requirements.⁵⁸

The chatbot's documented inaccuracies highlight critical accountability considerations in AI-driven care. While no malpractice litigation has been publicly reported, the potential for misdiagnoses to delay care or prompt inappropriate self-treatment underscores the need for rigorous validation, transparent performance metrics, and clear protocols to delineate responsibility among developers, healthcare providers, and institutions. Babylon's bankruptcy in 2023, driven by financial and operational challenges, further emphasizes the importance of robust clinical validation and transparent communication to ensure sustainable and safe AI deployment.⁵⁹

⁵⁶ Fraser, Hamish, et al. "Safety of Patient-facing Digital Symptom Checkers." *The Lancet* 392, no. 10161 (2018): 2263-2264.

⁵⁷ Medicines and Healthcare products Regulatory Agency, "Regulatory Guidance on AI as a Medical Device," MHRA, 2021.

⁵⁸ 15 U.S.C. § 6502(b)(1)(A)(ii) (COPPA).

⁵⁹ Wired UK, "Babylon Health's collapse shows the limits of AI hype," August 2023.

The collapse of Babylon Health illustrates that the absence of rigorous clinical validation and clear regulatory frameworks not only exposes patients to unsafe diagnoses but also undermines the business sustainability of digital health projects. For pediatric populations, where diagnostic risks and privacy obligations are heightened, this case highlights the importance of developing specialized regulatory pathways and reinforced safety protocols to mitigate clinical harm and strengthen implementation.

H.4. SUCCESSFUL IMPLEMENTATIONS: RADIOLOGY CAD SYSTEMS

Unlike consumer-facing systems such as Babylon, which demonstrated significant shortcomings in validation and regulatory compliance, radiology CAD systems demonstrate the potential for successful AI integration in healthcare, particularly through robust validation and clear regulatory pathways that enhance diagnostic precision in both general and pediatric applications.⁶⁰ By identifying subtle patterns in imaging data, these tools improve early detection of conditions such as breast cancer and lung nodules, augmenting human expertise in high-stakes diagnostics.⁶¹

The efficacy of modern CAD tools stems from advanced machine learning techniques trained on diverse imaging datasets, incorporating robust validation to ensure consistent performance across varied healthcare settings.⁶² This contrasts with earlier AI applications, addressing portability issues seen in systems like Watson or Babylon's chatbot.

Evolving regulatory frameworks have facilitated the safe adoption of CAD systems, with the FDA approving multiple tools under the 510(k) pathway and issuing guidance for AI-enabled device software functions in 2025.⁶³ This clarity mitigates oversight gaps observed in prior clinical decision support tools, enabling efficient deployment.

Effective integration of CAD tools into radiological practice requires balancing algorithmic outputs with independent judgment to avoid diagnostic errors from

⁶⁰ Gulshan, V., et al. "Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs." *JAMA* 316, no. 22 (2016): 2402-2410.

⁶¹ Reardon, "Rise of the robot radiologists," *Nature* 574, no. 7777 (2019): S24-S26.] [18: Topol, "High-performance medicine: The convergence of human and artificial intelligence," *Nature Medicine* 25, no. 1 (2019): 44-56.

⁶² Gulshan et al., "Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs," *JAMA* 316, no. 22 (2016): 2402-2410.

⁶³ Food and Drug Administration, "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations," FDA-2024-D-4488 (2025).

overreliance or underutilization.⁶⁴ Emerging considerations include potential liability risks when radiologists defer excessively to AI, necessitating clear protocols and training to optimize workflow integration and ensure accountability.⁶⁵ Ongoing efforts to address biases in training data and ensure equitable performance across diverse populations remain critical, supported by post-market surveillance to maintain safety and efficacy.⁶⁶

I. RECOMMENDATIONS AND IMPLEMENTATION ROADMAP

The lessons derived from the case studies analyzed above underscore the need for actionable strategies to address AI's implementation challenges, particularly for safeguarding pediatric populations in healthcare settings. Implementation success depends on establishing clear milestones, accountability mechanisms, and measurable performance indicators that align governance artifacts with existing clinical workflows and quality improvement cycles. Pediatric-specific adaptations must address unique developmental considerations, family-centered care requirements, and long-term outcome monitoring needs that distinguish child healthcare from adult-oriented AI applications.

Moving from principles to repeatable practices demands systematic attention to auditability, scalability, and clinical integration challenges that determine whether AI implementations enhance or disrupt patient care delivery. Regulatory pathways must accommodate AI system dynamism while maintaining safety standards, healthcare institutions require comprehensive governance structures for lifecycle management, and technology developers must prioritize equity, transparency, and clinical usability from initial design through post-market surveillance.

Coordinated stakeholder action becomes essential given the interdependent nature of AI healthcare ecosystems where regulatory gaps, institutional implementation failures, or technology design shortcomings can undermine system-wide safety and effectiveness regardless of individual component quality.

⁶⁴ Topol, "High-performance medicine: The convergence of human and artificial intelligence," *Nature Medicine* 25, no. 1 (2019): 44-56.

⁶⁵ Food and Drug Administration, "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations," FDA-2024-D-4488 (2025).

⁶⁶ Reardon, "Rise of the robot radiologists," *Nature* 574, no. 7777 (2019): S24-S26.

I.1. FOR REGULATORS AND POLICYMAKERS

Establishing specialized pediatric AI review pathways within FDA represents a critical priority that recognizes the unique validation requirements and safety considerations for AI systems serving pediatric populations. These pathways should require age-stratified clinical trials, developmental expertise on review panels, and enhanced post-market surveillance for long-term outcomes that may not appear until years after initial deployment.

Developing AI transparency standards must balance intellectual property protection with clinical accountability needs. Regulations should require disclosure of training data sources, validation methodologies, known limitations, and performance metrics across demographic groups, while allowing protection of proprietary algorithms and trade secrets that do not affect clinical interpretation.

Creating liability safe harbors for healthcare providers who follow established AI system use protocols and maintain appropriate oversight responsibilities becomes essential for promoting responsible adoption. Safe harbor provisions should incentivize responsible AI adoption while ensuring that protection requires adherence to evidence-based implementation practices and ongoing competency maintenance.

Mandating algorithmic bias testing as part of regulatory approval processes requires specific requirements for evaluation across racial, ethnic, gender, age, and socioeconomic groups. Testing protocols should address both individual fairness and group fairness metrics, with particular attention to vulnerable populations that may be underrepresented in training data or affected by historical healthcare disparities.

Establishing federal AI in healthcare research funding specifically directed toward pediatric applications, bias mitigation, and health equity improvement becomes crucial for advancing the field responsibly. Funding priorities should emphasize collaborative research across institutions, development of synthetic data generation techniques, and creation of diverse training datasets that support equitable AI system development.

I.2. FOR HEALTHCARE INSTITUTIONS

Developing institutional AI governance committees with expertise spanning clinical medicine, health informatics, bioethics, health law, and health equity represents a

foundational requirement for responsible implementation. These committees should establish institutional policies for AI system evaluation, approval, and monitoring while providing ongoing oversight of AI implementation across clinical departments and service lines.

Implementing comprehensive AI system documentation requirements must track AI system involvement in clinical decisions, physician responses to AI recommendations, and rationale for accepting or rejecting algorithmic suggestions. Documentation systems should integrate with electronic health records while supporting both clinical care coordination and legal compliance needs.

Creating AI-specific quality assurance programs becomes essential for monitoring system performance, detecting bias or drift, and evaluating clinical outcomes associated with AI-assisted care. Quality programs should include regular performance audits, patient outcome tracking, and systematic evaluation of AI system impact on healthcare disparities within the institution's patient population.

Establishing patient communication protocols for AI system use ensures informed consent, provides clear explanation of AI involvement in care decisions, and offers opt-out mechanisms where clinically appropriate. Communication protocols should be age-appropriate for pediatric populations and culturally sensitive for diverse patient communities.

Developing vendor management frameworks specifically for AI system procurement must emphasize ongoing performance monitoring, liability allocation, and data governance requirements. Vendor agreements should include provisions for algorithm updates, bias mitigation, and performance deterioration remediation while maintaining appropriate intellectual property protections.

I.3. FOR TECHNOLOGY DEVELOPERS

Prioritizing diverse and representative training datasets that reflect the full spectrum of patients who will encounter AI systems in clinical settings becomes fundamental to equitable system development. Development processes should systematically address known sources of bias in healthcare data while incorporating multiple institutions, geographic regions, and patient populations in training and validation phases.

Designing explainability features that provide clinically meaningful insights into AI system decision-making without requiring extensive technical expertise from healthcare providers proves essential for clinical adoption. Explainability tools should offer different levels of detail appropriate for different clinical contexts and user sophistication while maintaining accuracy in their representation of system behavior.

Implementing continuous performance monitoring capabilities that detect system drift, bias introduction, or performance degradation in real-world deployment environments represents a critical technical requirement. Monitoring systems should provide automated alerts for performance changes and support rapid response protocols when safety or effectiveness concerns emerge.

Establishing pediatric-specific development protocols addresses the unique challenges of limited training data, developmental variability, and family-centered care requirements. Development protocols should include pediatric expertise throughout the design process and validation approaches that account for age-related physiological and behavioral differences.

Creating transparent update and change management processes maintains system performance while providing appropriate notice to clinical users and regulatory authorities. Change management should balance the benefits of continuous improvement with the need for stability and predictability in clinical care environments.

I.4. PEDIATRIC-SPECIFIC IMPLEMENTATION PRIORITIES

Developing pediatric AI competency requirements for healthcare providers working with children addresses developmental considerations, family dynamics, and age-appropriate communication about AI involvement in care decisions. Competency frameworks should distinguish between different pediatric subspecialties and clinical contexts while ensuring baseline knowledge across all providers caring for children.

Creating specialized informed consent processes for pediatric AI applications must address parental permission, age-appropriate child assent, and long-term implications of AI-assisted care decisions. Consent processes should be developmentally appropriate and culturally sensitive while providing sufficient information for meaningful decision-making by families.

Establishing pediatric AI research consortiums facilitates data sharing, collaborative algorithm development, and multi-institutional validation studies across children's hospitals and pediatric practices. Consortiums should address technical, legal, and ethical barriers to pediatric AI research while promoting responsible innovation and knowledge sharing.

Developing pediatric AI safety metrics extends beyond traditional clinical endpoints to include developmental outcomes, educational impacts, family satisfaction, and long-term quality of life measures. Safety frameworks should recognize that pediatric AI impacts may not become apparent until years after initial deployment and require ongoing longitudinal monitoring.

Creating pediatric-specific bias evaluation protocols addresses the unique vulnerability factors affecting children, including the intersection of age with other demographic characteristics and the particular importance of equity in childhood healthcare that affects lifelong development and opportunities.

Implementation timeline recommendations suggest a phased approach beginning with low-risk applications in well-resourced settings with extensive oversight, gradually expanding to higher-risk applications and diverse settings as experience and evidence accumulate. This approach should prioritize pediatric safety while avoiding unnecessary delays in beneficial AI applications that could improve child health outcomes.

The successful implementation of these recommendations requires coordinated effort across regulatory agencies, healthcare institutions, technology companies, and professional organizations, with particular attention to the unique needs and vulnerabilities of pediatric populations who stand to benefit significantly from responsible AI innovation in healthcare.

J. CONCLUSIONS

The integration of artificial intelligence in U.S. healthcare has reached an inflection point where theoretical possibilities have become clinical realities, yet our legal and regulatory frameworks are still evolving to address the challenges this transformation presents. This analysis reveals that while significant progress has been made in establishing basic regulatory pathways through the FDA's evolving SaMD framework and the 21st Century

Cures Act's CDS provisions, important gaps persist that could strain both innovation and patient safety if not addressed.

Accountability remains a central challenge identified in this investigation. Current liability frameworks, developed for human decision-making, encounter limits when harm is linked to algorithmic bias, training data shortcomings, or the inherent opacity of some machine-learning systems. The traditional learned intermediary doctrine assumes physicians can meaningfully evaluate medical recommendations, yet AI tools may operate through decision pathways that are difficult to assess in practice. These features can create areas of uncertainty about responsibility allocation among physicians, hospitals, and technology vendors when AI systems fail.

Pediatric populations face particular vulnerabilities that existing frameworks only partially address. The combination of scarce training data, developmental variability, and long-term outcome implications creates a complex set of risk factors that warrants specialized regulatory attention. Our analysis indicates that some pediatric AI applications extrapolate from systems trained on adult populations without sufficient validation for developmental differences, which may affect care quality for vulnerable patients. The current regulatory approach often treats pediatric applications as adaptations of adult-oriented systems. Adopting a more pediatric-specific perspective would better reflect their distinct characteristics.

The transparency paradox emerges as a defining challenge where demands for algorithmic explainability conflict with both technical limitations and competitive pressures. Healthcare stakeholders require meaningful insights into AI decision-making to maintain professional responsibility and informed consent obligations, yet current technology may not be able to provide complete explanations of complex machine learning behavior. Legal frameworks must balance transparency requirements with recognition of technical limitations while preventing transparency demands from stifling beneficial innovation.

Equity concerns permeate every aspect of AI healthcare implementation, from training data selection through deployment context to outcome measurement. Our analysis demonstrates that AI systems can reflect and even amplify existing healthcare disparities without proactive design and continuous monitoring to prevent such outcomes. Current

regulatory frameworks do not yet provide robust mechanisms for identifying, measuring, and correcting algorithmic bias, particularly for pediatric populations where intersectional vulnerabilities compound traditional demographic disparities.

Regulatory fragmentation across FDA device oversight, HHS civil rights enforcement, state professional licensing, and emerging algorithmic accountability laws creates compliance complexity that particularly affects smaller healthcare institutions and pediatric specialty practices. This fragmentation is not unique to the U.S.; it mirrors a global challenge. The European Union's AI Act establishes a comprehensive, risk-based horizontal framework that would classify many healthcare AI systems as high-risk, imposing strict ex-ante requirements for conformity assessments, data governance, and transparency. Conversely, Canada's approach through Health Canada aligns more closely with the FDA's product-centric model but emphasizes “Good Machine Learning Practice” guiding principles throughout the lifecycle. Limited unified federal guidance in the U.S. can leave healthcare providers navigating potentially conflicting requirements while trying to implement beneficial AI technologies responsibly.

Looking toward solutions, this analysis identifies several critical priorities for legal framework evolution. First, specialized pediatric AI oversight pathways must be established that recognize developmental considerations and require age-stratified validation. Second, liability frameworks need fundamental reconceptualization to address shared responsibility among physicians, institutions, and technology vendors in AI-assisted care scenarios. Third, transparency requirements must balance meaningful disclosure with technical and competitive realities while ensuring that patients and providers receive actionable information about AI involvement in care decisions.

The path forward requires coordinated action across multiple stakeholders. Regulators must develop more nuanced oversight frameworks that accommodate AI system dynamism while maintaining safety standards. Healthcare institutions need comprehensive governance structures that can evaluate, implement, and monitor AI systems throughout their operational lifecycle. Technology developers must prioritize equity, transparency, and pediatric considerations from initial design through post-market surveillance.

Limitations of this analysis include the rapidly evolving nature of both technology and regulation, which means some findings may become outdated as new developments emerge. The limited body of jurisprudence specifically addressing healthcare AI creates uncertainty about how courts will ultimately resolve liability questions. International regulatory variations may influence U.S. approaches in ways not fully addressed in this domestic-focused analysis.

Future research priorities should emphasize longitudinal studies of pediatric AI outcomes, development of practical bias detection and mitigation techniques, and empirical evaluation of different liability allocation approaches. Legal scholarship must engage more deeply with technical aspects of AI systems while computer science research must consider legal and ethical implications throughout the development process.

The stakes are high. Healthcare AI has the potential to substantially improve diagnostic accuracy, reduce treatment errors, and expand access to specialized care, particularly benefiting underserved pediatric populations. However, gaps in legal frameworks could allow systems to perpetuate inequities, weaken professional accountability, or inadvertently harm patients if not addressed.

The window for proactive legal framework development is narrowing as AI adoption accelerates across healthcare settings. Policymakers, healthcare leaders, and technology developers must act decisively to establish governance structures that promote beneficial innovation while protecting patient safety and rights. The children who will grow up in an AI-enhanced healthcare system deserve nothing less than our most thoughtful and comprehensive approach to these challenges.

The future of healthcare AI will be determined not by technological capability alone, but by our collective wisdom in creating legal and ethical frameworks that harness this power responsibly. This is our moment to get it right.

K. BIBLIOGRAPHY

U.S. Legislation and Regulation

21st Century Cures Act, Pub. L. No. 114-255, § 3060 (2016).

Children's Online Privacy Protection Act (COPPA), 15 U.S.C. §§ 6501-6506 (2013).

Health Insurance Portability and Accountability Act (HIPAA), Pub. L. No. 104-191 (1996).

Health Information Technology for Economic and Clinical Health Act (HITECH), Pub. L. No. 111-5 (2009).

21 C.F.R. § 820 (Quality System Regulation) (2024).

21 U.S.C. § 360n-2 (Ensuring Cybersecurity of Medical Devices) (2022).

FDA Guidance Documents

Food and Drug Administration. Clinical Decision Support Software - Guidance for Industry and FDA Staff (Final Guidance). Sept. 28, 2022.

Food and Drug Administration. Software as a Medical Device (SaMD): Clinical Evaluation. FDA-2016-D-2483 (2017).

Food and Drug Administration. Machine Learning-enabled Medical Devices: Guiding Principles. FDA-2021-D-0538 (2021).

Food and Drug Administration. Predetermined Change Control Plans for Machine Learning-enabled Medical Device Software as a Medical Device. FDA-2023-D-1185 (2024).

Food and Drug Administration. Draft Guidance on Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. FDA-2024-D-4488 (2025)

Federal Case Law

Loomis v. Wisconsin, 371 Wis. 2d 235, 881 N.W.2d 749 (2016).

Carpenter v. United States, 138 S. Ct. 2206 (2018).

Benavides v. Tesla, Inc., No. 21-cv-21940-BB (S.D. Fla. verdict Aug. 1, 2025) (autonomous vehicle liability; jury verdict, post-trial motions pending).

Academic Literature - Legal

Hoffman, Sharona, and Andy Podgurski. "Artificial Intelligence and Discrimination in Health Care." *Yale Journal of Health Policy, Law, and Ethics* 19, no. 2 (2019): 1-49.

Price, W. Nicholson II. "Black-Box Medicine." *Harvard Journal of Law & Technology* 28, no. 2 (2015): 419-467.

Kesselheim, Aaron S., and Michelle M. Mello. "Medical-Device Regulation in the Era of Artificial Intelligence." *New England Journal of Medicine* 383 (2020): 101-103.

Cohen, I. Glenn, et al. "The Legal and Ethical Concerns that Arise from Using Complex Predictive Analytics in Health Care." *Health Affairs* 33, no. 7 (2014): 1139-1147.

Academic Literature - Medical and Pediatric

Rajkomar, Alvin, et al. "Machine Learning in Medicine." *New England Journal of Medicine* 380, no. 14 (2019): 1347-1358. DOI: 10.1056/NEJMra1814259.

Obermeyer, Ziad, et al. "Dissecting Racial Bias in an Algorithm Used to Manage the Health of Populations." *Science* 366, no. 6464 (2019): 447-453. DOI: 10.1126/science.aax2342.

Chen, Irene Y., et al. "Ethical Machine Learning in Healthcare." *Annual Review of Biomedical Data Science* 4 (2021): 123-144. DOI: 10.1146/annurev-biodatasci-092420-114104.

Topol, Eric J. "High-performance Medicine: The Convergence of Human and Artificial Intelligence." *Nature Medicine* 25, no. 1 (2019): 44-56. DOI: 10.1038/s41591-018-0300-7.

Burns, Matthew L., et al. "Pediatric Clinical Decision Support Systems: A Systematic Review and Meta-analysis." *JAMA Pediatrics* 174, no. 12 (2020): 1184-1194. DOI: 10.1001/jamapediatrics.2020.1546.

Wong, Andrew, et al. "External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients." *JAMA Internal Medicine* 181, no. 8 (2021): 1065–1070. DOI: 10.1001/jamainternmed.2021.2626.

Sendak, Mark, et al. "Real-World Integration of a Sepsis Deep Learning Technology." *NPJ Digital Medicine* 3, no. 143 (2020). DOI: 10.1038/s41746-020-00347-2.

Lee, J., et al. "The Challenges of Implementing AI in Global Healthcare: Lessons from Watson for Oncology." *Journal of Medical Systems* 42, no. 10 (2018): 187. DOI: 10.1007/s10916-018-1047-7.

Somashekhar, S. P., et al. "Watson for Oncology and Breast Cancer Treatment Recommendations: Agreement with Physicians." *Journal of Clinical Oncology* 36, no.

15_suppl (2018): e18595. DOI: 10.1200/JCO.2018.36.15_suppl.e18595.

Fraser, Hamish, et al. "Safety of Patient-Facing Digital Symptom Checkers." *The Lancet* 392, no. 10161 (2018): 2263-2264. DOI: 10.1016/S0140-6736(18)32819-8.

Brazelton, T. Berry. "Infants and Mothers: Differences in Development." New York: Delta, 1969.

Korczak, Janusz. "How to Love a Child." New York: Farrar, Straus and Giroux, 2007.

Dolto, Françoise. "The Case of the Child: The Child as a Subject." London: Karnac, 1988.

Exeni, Ramón A. "Carta de los Derechos del Niño Hospitalizado." Buenos Aires: Ministerio de Salud de la Nación, 1986.

Academic Literature - Technical and AI

Russell, Stuart, and Peter Norvig. *Artificial Intelligence: A Modern Approach*. 4th ed. Boston: Pearson, 2020.

Goodfellow, Ian, Yoshua Bengio, and Aaron Courville. *Deep Learning*. Cambridge: MIT Press, 2016.

Lipton, Zachary C. "The Mythos of Model Interpretability." *Communications of the ACM* 61, no. 10 (2018): 36-43. DOI: 10.1145/3233231.

Doshi-Velez, Finale, and Been Kim. "Towards a Rigorous Science of Interpretable Machine Learning." arXiv preprint arXiv:1702.08608 (2017). Available at: <https://arxiv.org/abs/1702.08608>.

Leveson, Nancy G., and John P. Thomas. "STPA Handbook." MIT Partnership for Systems Approaches to Safety (2018). Available at: <http://psas.scripts.mit.edu/home/materials/>.

Professional Organizations and Standards

American Medical Association. *Augmented Intelligence in Health Care*. AMA Policy H-480.940 (2018).

American Academy of Pediatrics. *Ethical Considerations for Including Children in Health Technology and Clinical Research*. *Pediatrics* 132, no. 5 (2013): 1034-1041. DOI: 10.1542/peds.2013-2580.

National Academy of Medicine. *Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril*. Washington, DC: National Academies Press, 2019. DOI: 10.17226/25468.

NIST. AI Risk Management Framework (AI RMF 1.0). NIST AI 100-1 (2023).

Available at: <https://nvlpubs.nist.gov/nistpubs/ai/NIST.AI.100-1.pdf>.

International and Comparative Sources

European Union. Regulation (EU) 2024/1689 on Artificial Intelligence (AI Act) (2024).

Health Canada. Good Machine Learning Practice for Medical Device Development:

Guiding Principles. HC Publication 21-115361 (2021). Available at:

<https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements.html>.

UK Department of Health and Social Care. A Guide to Good Practice for Digital and Data-Driven Health Technologies. London: DHSC, 2021.

Reports and White Papers

McKinsey Global Institute. The Age of AI: Artificial Intelligence and the Future of Work and Society. McKinsey & Company, 2023.

Brookings Institution. Algorithmic Bias Detection and Mitigation: Best Practices and Policies to Reduce Consumer Harms. Washington, DC: Brookings, 2019. Available at:

<https://www.brookings.edu/research/algorithmic-bias-detection-and-mitigation/>.

Partnership on AI. Algorithmic Risk Assessment Tool for Healthcare. San Francisco: Partnership on AI, 2020.

Bipartisan Policy Center. Artificial Intelligence and Health Care: Policy Considerations for Congress. Washington, DC: BPC, 2021.

News Articles

Ross, Casey, and Ike Swetlitz. "IBM Pitched Watson as a Revolution in Cancer Care. It's Nowhere Close." STAT News, September 5, 2017. Available at:

<https://www.statnews.com/2017/09/05/watson-ibm-cancer/>.

Wired UK. "Babylon Health's Collapse Shows the Limits of AI Hype." August 2023.

Available at: <https://www.wired.co.uk/article/babylon-health-collapse-ai-hype>.